Methods of prognosis and diagnosis of rheumatoid arthritis
AssigneeAbbott Japan Co., Ltd.
InventorsKaori Morota, Ryotaro Chiba, Rika Sekiya
Life of this patent
Estimating the term…
Abstract
Provided are methods of diagnosing rheumatoid arthritis in a patient by detecting the presence and/or amount of a biomarker of rheumatoid arthritis in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having rheumatoid arthritis or suspected of having rheumatoid arthritis, or to accurately diagnose a patient having, or suspected of having rheumatoid arthritis. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for a rheumatoid arthritis therapy.
Claims23
A method for providing a diagnosis, prognosis or risk classification of a subject having or at risk of having rheumatoid arthritis, the method comprising the steps of:
- a. determining the concentration of TARC/CCL17 in a biological sample of the subject;
- and
- b. comparing the TARC/CCL17 concentration from the sample to a reference TARC/CCL17 concentration value, wherein a TARC/CCL17 concentration in the sample greater than reference TARC/CCL17 concentration value indicates the subject has rheumatoid arthritis or has an increased risk of developing rheumatoid arthritis.
The method of any of the preceding claims, wherein the reference TARC/CCL17 concentration value is a TARC/CCL17 concentration value of a control sample, or a TARC/CCL17 cutoff value.
The method of any of the preceding claims, wherein the TARC/CCL17 concentration is the TARC/CCL17 concentration in serum.
The method of any of the preceding claims, wherein the method further comprises providing a diagnosis of rheumatoid arthritis.
The method of any of the preceding claims, wherein the method comprises providing a prognosis selected from determining the severity of rheumatoid arthritis in the subject and a likelihood that the subject will develop rheumatoid arthritis.
The method of any of the preceding claims, wherein the subject is a human.
The method of any of the preceding claims, wherein the biological sample of a subject is selected from a tissue sample, bodily fluid, whole blood, plasma, serum, urine, bronchoalveolar lavage fluid, and a cell culture suspension or fraction thereof.
The method of any of the preceding claims, wherein the biological sample of a subject is blood plasma or blood serum.
The method of any of the preceding claims, wherein determining the concentration of TARC/CCL17 comprises an immunological method with molecules binding to the TARC/CCL 17.
A method for the diagnosis, prognosis and/or risk stratification of rheumatoid arthritis in a subject having or suspected of having rheumatoid arthritis, the method comprising the step of detecting an increased TARC/CCL17 concentration in the subject relative to a control subject not having rheumatoid arthritis.
A kit for performing the method of any of the preceding claims, the kit comprising:
- a. at least one reagent capable of specifically binding TARC/CCL17 to quantify the TARC/CCL17 concentration in the biological sample of a subject;
- and
- b. a reference standard indicating a reference TARC/CCL17 concentration.
Dependencies are inferred from the claim text.